HC Wainwright Lowers Plus Therapeutics (NASDAQ:PSTV) Price Target to $2.00

Plus Therapeutics (NASDAQ:PSTV) had its price objective decreased by equities research analysts at HC Wainwright from $3.00 to $2.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price indicates a potential upside of 268.32% from the company’s previous close.

Other equities analysts also recently issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a report on Wednesday, October 8th. Zacks Research raised shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 13th. Wall Street Zen upgraded shares of Plus Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, August 16th. D. Boral Capital reissued a “buy” rating and issued a $5.00 target price on shares of Plus Therapeutics in a research note on Friday. Finally, D Boral Capital upgraded shares of Plus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Wednesday, September 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $7.75.

Plus Therapeutics Stock Up 2.5%

Shares of PSTV opened at $0.54 on Monday. Plus Therapeutics has a fifty-two week low of $0.16 and a fifty-two week high of $2.31. The company’s fifty day moving average is $0.56 and its two-hundred day moving average is $0.50. The firm has a market cap of $53.90 million, a PE ratio of -0.24 and a beta of 0.81.

Plus Therapeutics (NASDAQ:PSTV) last issued its earnings results on Thursday, October 30th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The company had revenue of $1.40 million during the quarter, compared to analyst estimates of $1.50 million. As a group, equities research analysts anticipate that Plus Therapeutics will post -2.3 earnings per share for the current year.

Insider Activity

In other Plus Therapeutics news, Director Robert P. Lenk purchased 110,000 shares of the business’s stock in a transaction that occurred on Friday, August 22nd. The shares were acquired at an average price of $0.49 per share, for a total transaction of $53,900.00. Following the completion of the purchase, the director owned 139,327 shares in the company, valued at $68,270.23. The trade was a 375.08% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.79% of the company’s stock.

Institutional Investors Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. Jane Street Group LLC bought a new stake in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 117,454 shares of the company’s stock, valued at approximately $41,000. Jane Street Group LLC owned about 0.19% of Plus Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.